Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis.
Xueshan SunXuemei ZhenXiaoqian HuYuanyuan LiShuYan GuYuxuan GuZixuan ZhaoWei YangHengjin DongPublished in: Cost effectiveness and resource allocation : C/E (2021)
The addition of a proton pump inhibitor to both imrecoxib and diclofenac was advised. Imrecoxib provides a valuable option for patients with osteoarthritis. Uncertainties existed in the model, and the suggestions can be adopted with caution.
Keyphrases